Precision Oncology: A Global Perspective on Implementation and Policy Development.

IF 3.2 Q2 ONCOLOGY JCO Global Oncology Pub Date : 2025-01-01 Epub Date: 2025-01-23 DOI:10.1200/GO-24-00416
Denis Horgan, Marcel Tanner, Charu Aggarwal, David Thomas, Surbhi Grover, Lina Basel-Salmon, Rodrigo Dienstmann, Tira Jing Ying Tan, Woong-Yang Park, Hadi Mohamad Abu Rasheed, Lillian L Siu, Brigette Ma, Rocío Ortiz-López, Marc Van den Bulcke, Silvia Castillo Taucher, Andrea Ferris, Naureen Starling, Umberto Malapelle, John Longshore, Hugo Alberto Barrera Saldaña, Vivek Subbiah
{"title":"Precision Oncology: A Global Perspective on Implementation and Policy Development.","authors":"Denis Horgan, Marcel Tanner, Charu Aggarwal, David Thomas, Surbhi Grover, Lina Basel-Salmon, Rodrigo Dienstmann, Tira Jing Ying Tan, Woong-Yang Park, Hadi Mohamad Abu Rasheed, Lillian L Siu, Brigette Ma, Rocío Ortiz-López, Marc Van den Bulcke, Silvia Castillo Taucher, Andrea Ferris, Naureen Starling, Umberto Malapelle, John Longshore, Hugo Alberto Barrera Saldaña, Vivek Subbiah","doi":"10.1200/GO-24-00416","DOIUrl":null,"url":null,"abstract":"<p><p>Despite the acknowledged merits of precision oncology (PO) and its increasing global implementation, its full potential for advancing care and prevention remains unrealized. The benefits are currently accessible to only limited patient segments because of multifaceted barriers. Successful implementation hinges on various factors-scientific complexities not limited to technical, clinical, regulatory, economic, administrative, and health care policy-related challenges. From building infrastructure to the associated costs, including research and development, testing, processing, and trained personnel, a lack of alignment persists. Administrative alignment with regulatory and payor acceptance is crucial. Health care policy must adapt to the ongoing shift from a one-size-fits-all treatment to a personalized approach. Without official endorsement of long-term gains over short-term costs and the health establishment's readiness for innovation, PO prospects, even in prosperous economies, may stagnate. Lower-income countries face exacerbated challenges, intensifying barriers to adoption. Nevertheless, growing awareness and utilization, driven by recognized potential for patients and public health, along with successful examples and advocacy, are progressively influencing policy for a more inclusive and beneficial approach to PO adoption.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400416"},"PeriodicalIF":3.2000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO Global Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1200/GO-24-00416","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/23 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Despite the acknowledged merits of precision oncology (PO) and its increasing global implementation, its full potential for advancing care and prevention remains unrealized. The benefits are currently accessible to only limited patient segments because of multifaceted barriers. Successful implementation hinges on various factors-scientific complexities not limited to technical, clinical, regulatory, economic, administrative, and health care policy-related challenges. From building infrastructure to the associated costs, including research and development, testing, processing, and trained personnel, a lack of alignment persists. Administrative alignment with regulatory and payor acceptance is crucial. Health care policy must adapt to the ongoing shift from a one-size-fits-all treatment to a personalized approach. Without official endorsement of long-term gains over short-term costs and the health establishment's readiness for innovation, PO prospects, even in prosperous economies, may stagnate. Lower-income countries face exacerbated challenges, intensifying barriers to adoption. Nevertheless, growing awareness and utilization, driven by recognized potential for patients and public health, along with successful examples and advocacy, are progressively influencing policy for a more inclusive and beneficial approach to PO adoption.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
相关文献
[Improved profitability and indications for blood culture extraction in emergency departments: another step forward].
IF 1.9 4区 医学Revista Espanola De QuimioterapiaPub Date : 2023-02-01 DOI: 10.37201/req/075.2022
I Nieto Rojas, W E López Forero
来源期刊
JCO Global Oncology
JCO Global Oncology Medicine-Oncology
CiteScore
6.70
自引率
6.70%
发文量
310
审稿时长
7 weeks
期刊最新文献
Addressing the Oncologist Shortage in Latin America: Insights From a Survey of Medical Oncology Fellowship Programs. Impact of Funding Source on Long-Term Outcomes in Prostate Cancer: Analysis of a Large Public Database From Sao Paulo, Brazil. Prognostic Modeling for Bone Sarcomas Based on a Large Prospective Cohort From a Tertiary Care Cancer Center in India. Self-Perceived Barriers to Pediatric Cancer Care in Sub-Saharan Africa: A Cross-Sectional Multinational Study. Spotlight on Lung Cancer Disparities in India.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1